Treatment of primary breast cancer with chemotherapy and tamoxifen
B Fisher, C Redmond, A Brown, N Wolmark, J Wittliff, ER Fisher, D Plotkin, D Bowman, S Sachs, J Wolter, R Frelick, R Desser, N LiCalzi, P Geggie, T Campbell, EG Elias, D Prager, P Koontz, H Volk, N Dimitrov, B Gardner, H Lerner, and H Shibata
We studied the possibility that the addition of tamoxifen to L-phenylalanine mustard combined with 5-fluorouracil enhances the benefit from the latter two drugs that has been observed in women with primary breast cancer and positive axillary nodes. Recurrence of disease was reduced at two years in patients given the three-drug regimen whose tumor estrogen-receptor levels were greater than or equal to 10 fmol. Among patients greater than or equal to 50 years old treatment failure was significantly reduced (P less than 0.001): by 51 per cent in those with one to three positive nodes and by 64 per cent in those with four or more. Higher receptor levels were associated with a greater probability of disease-free survival. Patients less than or equal to 49 years old were less responsive: those with one to three positive nodes received no benefit from tamoxifen at any receptor level, whereas those with four or more appeared to have reduced treatment failure associated with higher receptor levels. This adjuvant chemotherapy is not indicated in patients less than or equal to 49 years old whose tumor receptor levels are below 10 fmol; there is a suggestion of benefit in patients greater than or equal to 50 years old whose levels are low.
This article has been cited by other articles:
Fisher, B., Redmond, C. K., Fisher, E. R.
(2008). Evolution of Knowledge Related to Breast Cancer Heterogeneity: A 25-Year Retrospective. JCO
26: 2068-2071
[Full Text]
International Breast Cancer Study Group,
(2006). Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer: International Breast Cancer Study Group Trial 13-93. JCO
24: 1332-1341
[Abstract][Full Text]
Hutchins, L. F., Green, S. J., Ravdin, P. M., Lew, D., Martino, S., Abeloff, M., Lyss, A. P., Allred, C., Rivkin, S. E., Osborne, C. K.
(2005). Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102. JCO
23: 8313-8321
[Abstract][Full Text]
Pico, C., Martin, M., Jara, C., Barnadas, A., Pelegri, A., Balil, A., Camps, C., Frau, A., Rodriguez-Lescure, A., Lopez-Vega, J. M., de la Haba, J., Tres, A., Alvarez, I., Alba, E., Arcusa, A., Oltra, A., Batista, N., Checa, T., Perez-Carrion, R., Curto, J.
(2004). Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol
15: 79-87
[Abstract][Full Text]
Mustacchi, G., Ceccherini, R., Milani, S., Pluchinotta, A., De Matteis, A., Maiorino, L., Farris, A., Scanni, A., Sasso, F.
(2003). Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol
14: 414-420
[Abstract][Full Text]
Harlan, L. C., Abrams, J., Warren, J. L., Clegg, L., Stevens, J., Ballard-Barbash, R.
(2002). Adjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians. JCO
20: 1809-1817
[Abstract][Full Text]
Goldhirsch, A., Gelber, R. D., Yothers, G., Gray, R. J., Green, S., Bryant, J., Gelber, S., Castiglione-Gertsch, M., Coates, A. S.
(2001). Adjuvant Therapy for Very Young Women With Breast Cancer: Need for Tailored Treatments. J Natl Cancer Inst Monogr
2001: 44-51
[Abstract][Full Text]
Swain, S. M.
(2001). Tamoxifen for Patients With Estrogen Receptor-Negative Breast Cancer. JCO
19: 93s-97
[Full Text]
Wickerham, D. L.
(2001). Ductal Carcinoma-In-Situ. JCO
19: 98s-100
[Full Text]
Fisher, B., Anderson, S., Tan-Chiu, E., Wolmark, N., Wickerham, D. L., Fisher, E. R., Dimitrov, N. V., Atkins, J. N., Abramson, N., Merajver, S., Romond, E. H., Kardinal, C. G., Shibata, H. R., Margolese, R. G., Farrar, W. B.
(2001). Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23. JCO
19: 931-942
[Abstract][Full Text]
Fisher, B., Anderson, S., DeCillis, A., Dimitrov, N., Atkins, J. N., Fehrenbacher, L., Henry, P. H., Romond, E. H., Lanier, K. S., Davila, E., Kardinal, C. G., Laufman, L., Pierce, H. I., Abramson, N., Keller, A. M., Hamm, J. T., Wickerham, D.L., Begovic, M., Tan-Chiu, E., Tian, W., Wolmark, N.
(1999). Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25. JCO
17: 3374-3388
[Abstract][Full Text]
Hornykiewicz, O.
(1998). Biochemical aspects of Parkinson's disease. Neurology
51: S2-S9
[Abstract][Full Text]
Sourla, A., Luo, S., Labrie, C., Belanger, A., Labrie, F.
(1997). Morphological Changes Induced by 6-Month Treatment of Intact and Ovariectomized Mice with Tamoxifen and the Pure Antiestrogen EM-800. Endocrinology
138: 5605-5617
[Abstract][Full Text]
Waters, C. H.
(1997). Managing the late complications of Parkinson's disease. Neurology
49: S49-S57
[Abstract][Full Text]
Moore, B. D. III, Slopis, J. M., Schomer, D., Jackson, E. F., Levy, B. M.
(1996). Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology
46: 1660-1668
[Abstract][Full Text]
Ellis, L. M., Wittliff, J. L., Bryant, M. S., Sitren, H. S., Hogancamp, W. E., Souba, W. W., Bland, K. I.
(1989). Lability of Steroid Hormone Receptors Following Devascularization of Breast Tumors. Arch Surg
124: 39-42
[Abstract]
